Molecular and Cell Biology

Mila Grinblat

Mila Grinblat

Dena Francis

Dena Francis

David Whitmore

David Whitmore

Margaret Jordan

Margaret Jordan

Patrick Schaeffer

Patrick Schaeffer

Sacha Jensen

Sacha Jensen

Lionel Hebbard

Lionel Hebbard

Craig McFarlane

Craig McFarlane

Alanna Sorenson

Alanna Sorenson

Alan Baxter

Alan Baxter

Mechanisms determining Marfan syndrome severity (Old ID 27110)
Sacha Jensen
01 Jan 2021 - 31 Dec 2023
Marfan syndrome (MFS), caused by defects in the protein fibrillin-1, has a wide spectrum of severity with symptoms affecting the heart, bones and eyes. The cause of this variation in severity is unclear. Severe, neonatal MFS and Beal's syndrome result from mutations in corresponding parts of the proteins fibrilin-1 and fibrillin-2. Using clues from these diseases, this project will use new cell engineering techniques to determine why some fibrillin mutations are more severe than others. The results are relevant not only to understanding MFS, but also to understanding how the tissues in our bodies are developed and maintained.
Improving Hepatocellular Carcinoma Immunotherapy
Craig McFarlane
31 Jul 2025 - 31 Dec 2026
Hepatocellular carcinoma (HCC) constitutes 80-90% of all liver cancers and is the third leading cause of cancer-related death globally. There are just a few therapeutic options available for HCC patients. The most promising is immunotherapy, which uses the antibodies atezolizumab, an immune check point inhibitor, and bevacizumab an angiogenic inhibitor, that direct the immune system to kill HCC tumour cells. However, immunotherapy is effective in just 30% of HCC patients and can in some instances promote tumour progression and have adverse effects. The major reason for this is that the HCC immune environment is immunosuppressed in 70% of patients, and the molecular events leading to this are poorly understood. This project will use murine HCC models and atezolizumab and bevacizumab therapeutic equivalents, single cell sequencing and advanced cell biology to decipher how HCC escapes immunotherapy, and hence determine new therapeutic targets to treat immunosuppressed HCC.

Aptamers: a promising chemical antibody for cancer therapy

Hepatocellular carcinoma and non-alcoholic steatohepatitis: the state of play

Overcoming treatment resistance in cancer: current understanding and tactics

Common and low Frequency variants in MERTK are independently associated with multiple sclerosis susceptibility with discordant association dependent upon HLA-DRB1*15:01 status

The transcriptomic response of the coral Acropora digitifera to a competent Symbiodinium strain: the symbiosome as an arrested early phagosome

Near-future pH conditions severely impact calcification, metabolism and the nervous system in the pteropod Heliconoides inflatus

Complete mitochondrial genome sequences of Atlantic representatives of the invasive Pacific coral species Tubastraea coccinea and T. tagusensis (Scleractinia, Dendrophylliidae): implications for species identification

Corallimorpharians are not "naked corals": insights into relationships between Scleractinia and Corallimorpharia from phylogenomic analyses

The functional roles of T-cadherin in mammalian biology

Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors

Title: PhD, University of Waikato
Reseracher: Craig McFarlane (Associate Professor)
Start Date: 01 Jan 2003
End Date: 01 Jan 2007
Title: MSc (first class honours), University of Waikato
Reseracher: Craig McFarlane (Associate Professor)
Start Date: 01 Jan 2001
End Date: 01 Jan 2003
Title: BSc (Tech), University of Waikato
Reseracher: Craig McFarlane (Associate Professor)
Start Date: 01 Jan 1996
End Date: 01 Jan 2000
Title: 2024 North Queensland Sustainable Innovation Showcase, Climate Salad
Reseracher: Craig McFarlane (Associate Professor)
Title: The cellular agriculture ecosystem in Australia, Cellular Agriculture Australia
Reseracher: Craig McFarlane (Associate Professor)
Title: CSIRO, A public showcase event where we presented information about Infinite Bioworks to the Australian public and potential investors.
Reseracher: Craig McFarlane (Associate Professor)
Start Date: 01 Jan 2024
End Date: 01 Jan 2024
Title: CSIRO, Investor Demo Day, where we presented our Infinite Bioworks venture to investors, industry, and the broader ecosystem.
Reseracher: Craig McFarlane (Associate Professor)
Start Date: 01 Jan 2024
End Date: 01 Jan 2024
Title: JCU funded travel [$1500]
Reseracher: Margaret Jordan (Senior Research Fellow)
Start Date: 01 Jan 2016
Title: AI on NHMRC grant #1061580 (Novel posttranscriptional pathways that control Tfh cell numbers. CIA Prof Carola Vinuesa CIB Dr Julia Ellyard, ANU $626 226.00
Reseracher: Margaret Jordan (Senior Research Fellow)
Start Date: 01 Jan 2014
Title: RIBG [$109 000]
Reseracher: Margaret Jordan (Senior Research Fellow)
Start Date: 01 Jan 2015